Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

By S. Jiralerspong, S. Palla, S. Giordano, Funda Meric-Bernstam, C. Liedtke, C. Barnett, L. Hsu, M. Hung, G. Hortobagyi, A. González-Angulo. Journal of Clinical Oncology, 2009

880 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/7093b7f480aab619c6fb285a03a00d8714907996

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

The LKB1-AMPK pathway: metabolism and growth control in tumor suppression (2009, background): “Similarly, a recent study of breast cancer in patients with type 2 diabetes who were taking metformin reported a significant increase in pathological complete response rates (that is, no evidence of cancer cells in breast tissue or draining lymph nodes”
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission (2009, background): “October 1, 2009 OF4 www.aacrjournals.org epidemiologic observation that diabetics treated with metformin have a lower incidence of cancer (5, 6 ). As a cancer preventative, metformin would be required on a long-term basis, and in this regard, the concentration of metformin needed for the anticancer”
Triple-negative breast cancer: disease entity or title of convenience? (2010, background): “There is also evidence that metformin may enhance the efficacy of chemotherapy in patients with breast cancer (of unspecified molecular subtype”
Targeting metabolic transformation for cancer therapy (2010, background): “A further study on diabetic patients with breast cancer as well as studies on breast cancer cells in vitro and a mouse model of breast cancer also found an anti-tumour effect of metformi”
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “Furthermore, a retrospective study linked metformin use with a higher probability of pCR in the neoadjuvant setting.(77) Taking all of this together, the use of metformin in breast cancer treatment looks very promising and several clinical trials are exploring the usefulness of this drug in advanced”
Targeting Metabolism for Cancer Therapy (2017, background): “Metformin has also been found to cooperate with neo-adjuvant chemotherapy to result in complete tumor regression in some breast cancer patients (Jiralerspong et al., 2009).”
Targeting cancer metabolism: a therapeutic window opens (2011, background): “, and women taking metformin have an increased tumour response to neoadjuvant chemotherapy for breast cancer that may extend to patients with cancer who do not have diabete”
Diabetes and Cancer (2010, neutral): “Metformin treatment was associated with higher pathologic complete response among early-stage breast cancer patients receiving neoadjuvant therapy (95).”
Network-based machine learning and graph theory algorithms for precision oncology (2017, background): “104 Similarly, the loss of the AMPK activator LKB1 promotes endometrial cancer progression and metastasis, 105, 106 implicating the AMPK pathway in endometrial cancer, and metformin inhibits endometrial cancer cell proliferation.”